BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 25288723)

  • 1. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
    Kiiski JI; Pelttari LM; Khan S; Freysteinsdottir ES; Reynisdottir I; Hart SN; Shimelis H; Vilske S; Kallioniemi A; Schleutker J; Leminen A; Bützow R; Blomqvist C; Barkardottir RB; Couch FJ; Aittomäki K; Nevanlinna H
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15172-7. PubMed ID: 25288723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
    Kiiski JI; Tervasmäki A; Pelttari LM; Khan S; Mantere T; Pylkäs K; Mannermaa A; Tengström M; Kvist A; Borg Å; Kosma VM; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Winqvist R; Nevanlinna H
    Breast Cancer Res Treat; 2017 Nov; 166(1):217-226. PubMed ID: 28702895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
    Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Shehzad U; Khan FA; Loya A; Hamann U
    Fam Cancer; 2023 Jan; 22(1):31-41. PubMed ID: 35802266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.
    Silvestri V; Rizzolo P; Zelli V; Valentini V; Zanna I; Bianchi S; Tibiletti MG; Varesco L; Russo A; Tommasi S; Coppa A; Capalbo C; Calistri D; Viel A; Cortesi L; Manoukian S; Bonanni B; Montagna M; Palli D; Radice P; Peterlongo P; Ottini L
    Breast; 2018 Apr; 38():92-97. PubMed ID: 29287190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
    Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan.
    Rashid MU; Muhammad N; Khan FA; Hamann U
    Breast Cancer Res Treat; 2015 Jul; 152(1):229-230. PubMed ID: 26067930
    [No Abstract]   [Full Text] [Related]  

  • 9. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.
    Catucci I; Osorio A; Arver B; Neidhardt G; Bogliolo M; Zanardi F; Riboni M; Minardi S; Pujol R; Azzollini J; Peissel B; Manoukian S; De Vecchi G; Casola S; Hauke J; Richters L; Rhiem K; Schmutzler RK; Wallander K; Törngren T; Borg Å; Radice P; Surrallés J; Hahnen E; Ehrencrona H; Kvist A; Benitez J; Peterlongo P
    Genet Med; 2018 Apr; 20(4):452-457. PubMed ID: 28837162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia.
    Kasak L; Punab M; Nagirnaja L; Grigorova M; Minajeva A; Lopes AM; Punab AM; Aston KI; Carvalho F; Laasik E; Smith LB; ; Conrad DF; Laan M
    Am J Hum Genet; 2018 Aug; 103(2):200-212. PubMed ID: 30075111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
    García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
    Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.
    Lim BWX; Li N; Mahale S; McInerny S; Zethoven M; Rowley SM; Huynh J; Wang T; Lee JEA; Friedman M; Devereux L; Scott RJ; Sloan EK; James PA; Campbell IG
    J Natl Cancer Inst; 2023 Feb; 115(2):181-189. PubMed ID: 36315097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing of Finnish hereditary breast cancer families.
    Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited predisposition to breast cancer among African American women.
    Churpek JE; Walsh T; Zheng Y; Moton Z; Thornton AM; Lee MK; Casadei S; Watts A; Neistadt B; Churpek MM; Huo D; Zvosec C; Liu F; Niu Q; Marquez R; Zhang J; Fackenthal J; King MC; Olopade OI
    Breast Cancer Res Treat; 2015 Jan; 149(1):31-9. PubMed ID: 25428789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Kiiski JI; Fagerholm R; Tervasmäki A; Pelttari LM; Khan S; Jamshidi M; Mantere T; Pylkäs K; Bartek J; Bartkova J; Mannermaa A; Tengström M; Kosma VM; Winqvist R; Kallioniemi A; Aittomäki K; Blomqvist C; Nevanlinna H
    Int J Cancer; 2016 Dec; 139(12):2760-2770. PubMed ID: 27542569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.
    Peterlongo P; Catucci I; Colombo M; Caleca L; Mucaki E; Bogliolo M; Marin M; Damiola F; Bernard L; Pensotti V; Volorio S; Dall'Olio V; Meindl A; Bartram C; Sutter C; Surowy H; Sornin V; Dondon MG; Eon-Marchais S; Stoppa-Lyonnet D; Andrieu N; Sinilnikova OM; ; Mitchell G; James PA; Thompson E; ; ; Marchetti M; Verzeroli C; Tartari C; Capone GL; Putignano AL; Genuardi M; Medici V; Marchi I; Federico M; Tognazzo S; Matricardi L; Agata S; Dolcetti R; Della Puppa L; Cini G; Gismondi V; Viassolo V; Perfumo C; Mencarelli MA; Baldassarri M; Peissel B; Roversi G; Silvestri V; Rizzolo P; Spina F; Vivanet C; Tibiletti MG; Caligo MA; Gambino G; Tommasi S; Pilato B; Tondini C; Corna C; Bonanni B; Barile M; Osorio A; Benitez J; Balestrino L; Ottini L; Manoukian S; Pierotti MA; Renieri A; Varesco L; Couch FJ; Wang X; Devilee P; Hilbers FS; van Asperen CJ; Viel A; Montagna M; Cortesi L; Diez O; Balmaña J; Hauke J; Schmutzler RK; Papi L; Pujana MA; Lázaro C; Falanga A; Offit K; Vijai J; Campbell I; Burwinkel B; Kvist A; Ehrencrona H; Mazoyer S; Pizzamiglio S; Verderio P; Surralles J; Rogan PK; Radice P
    Hum Mol Genet; 2015 Sep; 24(18):5345-55. PubMed ID: 26130695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.